Evidence map›Paper›PMID 38651154›Full record

ArticleFrontiers in oncology2024

Case report: Salivary duct carcinoma in a patient with a germline

Nidhi Desai, Emilian Racila, Naomi Fujioka, Arjun Gupta, Emmanuel S Antonarakis

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Nidhi DesaiDivision of Hematology, Oncology & Transplantation, University of Minnesota, Minneapolis, MN, United States.
Emilian RacilaDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States.
Naomi FujiokaDivision of Hematology, Oncology & Transplantation, University of Minnesota, Minneapolis, MN, United States.
Arjun Gupta *Division of Hematology, Oncology & Transplantation, University of Minnesota, Minneapolis, MN, United States.
Emmanuel S Antonarakis *Division of Hematology, Oncology & Transplantation, University of Minnesota, Minneapolis, MN, United States.
Minnesota Oncology · USUniversity of Minnesota · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
NCI NIH HHS P30 CA077598
6 · The paper itself

Abstract

Introduction: Recently, an entity known as salivary duct carcinoma with rhabdoid features (SDC-RF) has been associated with somatic Case discussion: A 67-year-old man presented with chest and back pain and was found to have osteolytic lesions in the sternum and lumbar spine. Vertebral bone biopsies were positive for metastatic carcinoma of unknown primary. A molecular profiling assay consisting of both whole-exome next-generation sequencing (NGS) as well as immunohistochemistry (IHC) for select clinically-relevant proteins performed on the bone biopsy suggested a triple-negative (ER/PR/ERBB2 negative, by IHC), androgen receptor (AR IHC) positive tumor profile. Additionally, the assay uncovered a coding mutation in the Conclusion: Molecular testing revealed that our patient had bi-allelic inactivation of the

Indexed as

cancerCDH1germlinepathogenic variantsalivary duct carcinoma

Identifiers

PMID38651154
PMCPMC11034483
OpenAlexW4394567939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.